Anne M Kerola1, Tuomo V M Nieminen2, Lauri J Virta3, Hannu Kautiainen4, Tuomas Kerola5, Timo Pohjolainen6, Markku J Kauppi7, Kari Puolakka8. 1. Medical School, University of Helsinki, Helsinki, Finland. 2. Department of Internal Medicine, University of Helsinki and Helsinki University Central Hospital; and Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland. 3. Research Department, the Social Insurance Institution, Turku, Finland. 4. Unit of Primary Health Care, Helsinki University Central Hospital; and Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland. 5. Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland. 6. ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland. 7. Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti; and School of Medicine, Tampere University, Tampere, Finland. 8. Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland.
Abstract
OBJECTIVES: To assess cardiovascular (CV) mortality in early rheumatoid arthritis (RA), and the impact of RA medications on CV mortality. METHODS: We identified all incident RA patients over 18 years of age diagnosed between 2000 and 2007 in Finland. Causes of death were analysed until the end of the year 2008. We used competing-risks regression models to assess the impact of different variables such as RA medications on CV mortality. CV mortality was compared with that of the age- and sex-specific general population. RESULTS: We identified 14,878 incident RA patients (68% women, 63% rheumatoid factor (RF) positive, mean age 55.8/57.5 years in men/women), of whom more than 80% received RA medications for longer than 90% of their individual patient-years. By the end of 2008, 1,157 patients died, 501 (43%) of whom of CV causes. The standardised mortality ratio (SMR) for CV deaths in the entire RA cohort was 0.57 (95% CI 0.52 to 0.62). Along with traditional CV risk factors, the presence of RF and the use of glucocorticoids was associated with a higher risk of CV death, whereas the use of methotrexate was associated with a lower risk. CONCLUSIONS: These nationwide results suggest that patients with recent-onset RA who receive consistent RA medication have no increased risk for CV mortality compared to the general population, at least in the early years of the disease. The use of methotrexate is associated with lower CV mortality, whereas the use of glucocorticoids is associated with a higher than average CV mortality.
OBJECTIVES: To assess cardiovascular (CV) mortality in early rheumatoid arthritis (RA), and the impact of RA medications on CV mortality. METHODS: We identified all incident RApatients over 18 years of age diagnosed between 2000 and 2007 in Finland. Causes of death were analysed until the end of the year 2008. We used competing-risks regression models to assess the impact of different variables such as RA medications on CV mortality. CV mortality was compared with that of the age- and sex-specific general population. RESULTS: We identified 14,878 incident RApatients (68% women, 63% rheumatoid factor (RF) positive, mean age 55.8/57.5 years in men/women), of whom more than 80% received RA medications for longer than 90% of their individual patient-years. By the end of 2008, 1,157 patients died, 501 (43%) of whom of CV causes. The standardised mortality ratio (SMR) for CV deaths in the entire RA cohort was 0.57 (95% CI 0.52 to 0.62). Along with traditional CV risk factors, the presence of RF and the use of glucocorticoids was associated with a higher risk of CV death, whereas the use of methotrexate was associated with a lower risk. CONCLUSIONS: These nationwide results suggest that patients with recent-onset RA who receive consistent RA medication have no increased risk for CV mortality compared to the general population, at least in the early years of the disease. The use of methotrexate is associated with lower CV mortality, whereas the use of glucocorticoids is associated with a higher than average CV mortality.
Authors: Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Garifallia Sakellariou; Carlo Alberto Scirè; Federica Rumi; Greta Carrara; Anna Zanetti; Carlo Cerra; Simona Migliazza; Serena Bugatti; Carlomaurizio Montecucco Journal: Arthritis Res Ther Date: 2022-06-16 Impact factor: 5.606
Authors: Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova Journal: Rheumatol Int Date: 2019-05-03 Impact factor: 2.631
Authors: Helen V Udachkina; Diana S Novikova; Tatiana V Popkova; Irina G Kirillova; Evgenia I Markelova Journal: Rheumatol Int Date: 2018-05-11 Impact factor: 2.631
Authors: Elena Myasoedova; John M Davis; Veronique L Roger; Sara J Achenbach; Cynthia S Crowson Journal: J Rheumatol Date: 2021-02-15 Impact factor: 5.346
Authors: Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho Journal: BMC Pulm Med Date: 2016-07-27 Impact factor: 3.317